Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

ClinicalTrials.gov ID: NCT00846586

Public ClinicalTrials.gov record NCT00846586. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study assessed the efficacy and safety of indacaterol (150 µg once daily \[od\]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease (COPD)

Study identification

NCT ID
NCT00846586
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
1,134 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2009
Primary completion
Feb 28, 2010
Completion
Feb 28, 2010
Last update posted
Aug 17, 2011

2009 – 2010

United States locations

U.S. sites
61
U.S. states
30
U.S. cities
56
Facility City State ZIP Site status
Novartis Investigator Site Birmingham Alabama 32509
Novartis Investigator Site Mobile Alabama 36608
Novartis Investigative Site Scottsdale Arizona 85258
Novartis Investigative Site Tucson Arizona 85712
Novartis Investigative Site Tucson Arizona 85723
Novartis Investigator Site Pine Bluff Arkansas 71603
Novartis Investigator Site Fountain Valley California 92708
Novartis Investigator Site Long Beach California 90822
Novartis Investigative Site Los Angeles California 90095
Novartis Investigator Site National City California 91950
Novartis Investigator Site Palmdale California 93551
Novartis Investigative Site Stockton California 95207
Novartis Investigator Site Temecula California 92591
Novartis Investigative Site Hartford Connecticut 06105-1208
Novartis Investigative Site Clearwater Florida 33756
Novartis Investigator Site Fort Walton Beach Florida 32547
Novartis Investigative Site Miami Florida 33136
Novartis Investigative Site Miami Florida 331577
Novartis Investigative Site Naranja Florida 33032
Novartis Investigator Site Pensacola Florida 32514
Novartis Investigator Site Sarasota Florida 34233
Novartis Investigative Site Atlanta Georgia 30342
Novartis Investigator Site Conyers Georgia 30094
Novartis Investigative Site Normal Illinois 61761
Novartis Investigative Site Iowa City Iowa 52240
Novartis Investigative Site Kansas City Kansas 66160
Novartis Investigative Site Lenexa Kansas 66215
Novartis Investigative Site Topeka Kansas 66606
Novartis Investigator Site Lafayette Louisiana 70503
Novartis Investigator Site Metaire Louisiana 70002
Novartis Investigator Site New Orleans Louisiana 70119
Novartis Investigator Site Slidell Louisiana 70458
Novartis Investigator Site Columbia Maryland 21044
Novartis Investigator Site Brockton Massachusetts 02301
Novartis Investigator Site Clarkston Michigan 48346
Novartis Investigator Site Detroit Michigan 48202
Novartis Investigative Site Saint Charles Missouri 63301
Novartis Investigator Site Missoula Montana 59808
Novartis Investigator Site Boys Town Nebraska 68010
Novartis Investigative Site Omaha Nebraska 68114
Novartis Investigative site Omaha Nebraska 68134
Novartis Investigative Site Las Vegas Nevada 89119
Novartis Investigator Site Lebanon New Hampshire 03756
Novartis Investigator Site Asbury Park New Jersey 07712
Novartis Investigative Site Rochester New York 14618
Novartis Investigator Site Mooresville North Carolina 28117
Novartis Investigative Site Winston-Salem North Carolina 27103
Novartis Investigator Site Tulsa Oklahoma 74135-2920
Novartis Investigative Site Medford Oregon 97504
Novartis Investigator Site Bethlehem Pennsylvania 18020
Novartis Investigative Site Cumberland Rhode Island 02864
Novartis Investigator Site Greenville South Carolina 29615
Novartis Investigative Site Spartanburg South Carolina 29303
Novartis Investigator Site Knoxville Tennessee 37919
Novartis Investigator Site El Paso Texas 79903
Novartis Investigative Site Houston Texas 77024
Novartis Investigative Site Houston Texas 77079
Novartis Investigative Center New Braunfels Texas 78130-6113
Novartis Investigator Site Newport News Virginia 23606
Novartis Investigative Site Richmond Virginia 23225
Novartis Investigator Site Richmond Virginia 23249

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00846586, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 17, 2011 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00846586 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →